Parallax Volatility Advisers
DRNA

Parallax Volatility Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Parallax Volatility Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-126,600
Closed -$2.28M – 3336
2020
Q3 		$2.28M Buy
+126,600
New +$2.62M ﹤0.01% 1633

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parallax Volatility Advisers's DRNA Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020, closing a stake of 18,388 shares — an estimated $331K sold.

Parallax Volatility Advisers first reported a position in DRNA in Q1 2018 and held it in 2 quarters. The position peaked at $331K in Q3 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 18,388 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $331K.
  • Parallax Volatility Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
  • Parallax Volatility Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $331K in Q3 2020.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.